Okładka

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine

Cefiderocol susceptibility testing represents a major challenge for clinical microbiology. Although disc diffusion showed robustness to test cefiderocol susceptibility, large areas of technical uncertainty (ATU) are reported by current EUCAST breakpoints. Herein, we evaluated the in vitro activity o...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	Gabriele Bianco (Autor), Matteo Boattini (Autor), Sara Comini (Autor), Giuliana Banche (Autor), Rossana Cavallo (Autor), Cristina Costa (Autor)
Format:	Książka
Wydane:	MDPI AG, 2023-03-01T00:00:00Z.
Hasła przedmiotowe:	article
Dostęp online:	Connect to this object online.
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
od: Gabriele Bianco, i wsp.
Wydane: (2022)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in <i>Acinetobacter baumannii</i>
od: Natalia Kolesnik-Goldmann, i wsp.
Wydane: (2023)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing <i>Klebsiella pneumoniae</i>
od: Federica Bovo, i wsp.
Wydane: (2023)

Comprehensive Statistical Evaluation of Etest<sup>®</sup>, UMIC<sup>®</sup>, MicroScan and Disc Diffusion versus Standard Broth Microdilution: Workflow for an Accurate Detection of Colistin-Resistant and <i>Mcr</i>-Positive <i>E. coli</i>
od: Isidro García-Meniño, i wsp.
Wydane: (2020)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
od: Michela Padovani, i wsp.
Wydane: (2023)

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals
od: Claudia Alteri, i wsp.
Wydane: (2024)

Challenges Facing Two Outbreaks of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
od: Montserrat Rodríguez-Aguirregabiria, i wsp.
Wydane: (2024)

The solution to drug resistance of Gram-negative bacteria - Cefiderocol
od: Magdalena Kołodziej, i wsp.
Wydane: (2023)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
od: Monirul I. Sajib, i wsp.
Wydane: (2023)

Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond
od: Davorka Repac Antić, i wsp.
Wydane: (2022)

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
od: Giovanna Travi, i wsp.
Wydane: (2024)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
od: Noël Zahr, i wsp.
Wydane: (2022)

Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant <it>P. aeruginosa </it>to polymyxins
od: Fung Liang, i wsp.
Wydane: (2007)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
od: Stamatis Karakonstantis, i wsp.
Wydane: (2022)

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
od: Cristina Kirkegaard-Biosca, i wsp.
Wydane: (2024)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
od: Arta Karruli, i wsp.
Wydane: (2023)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
od: Gabriele Palermo, i wsp.
Wydane: (2023)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
od: Julia Zimmer, i wsp.
Wydane: (2021)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
od: Andrea Marino, i wsp.
Wydane: (2022)

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains
od: Vincent Jean-Pierre, i wsp.
Wydane: (2024)

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
od: Yasaman Taheri, i wsp.
Wydane: (2021)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
od: Karol Lorenc Lorenc, i wsp.
Wydane: (2019)

Real-world clinical outcomes of cefiderocol therapy in the Veterans Health Administration, 2019-2022
od: Eva Amenta, i wsp.
Wydane: (2023)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
od: Karol Lorenc Lorenc, i wsp.
Wydane: (2019)

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
od: Silvia Corcione, i wsp.
Wydane: (2022)

Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
od: Pasquale Sansone, i wsp.
Wydane: (2022)

The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy
od: Stefania Mercadante, i wsp.
Wydane: (2023)

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus
od: Vincent Jean-Pierre, i wsp.
Wydane: (2024)

Evaluation of the BioFire<sup>®</sup> FilmArray<sup>®</sup> Blood Culture Identification Panel on positive blood cultures in a regional hospital laboratory in KwaZulu-Natal
od: Mokshanand Fhooblall, i wsp.
Wydane: (2016)

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
od: Simone Mornese Pinna, i wsp.
Wydane: (2022)

The Use of Cefiderocol in Gram-Negative Bacterial Infections at International Medical Center, Jeddah, Saudi Arabia
od: Reham Kaki, i wsp.
Wydane: (2024)

Nuclear Cross-Section of Proton-Induced Reactions on Enriched <sup>48</sup>Ti Targets for the Production of Theranostic <sup>47</sup>Sc Radionuclide, <sup>46c</sup>Sc, <sup>44m</sup>Sc, <sup>44g</sup>Sc, <sup>43</sup>Sc, and <sup>48</sup>V
od: Liliana Mou, i wsp.
Wydane: (2023)

Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study
od: Federica Calò, i wsp.
Wydane: (2023)

Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it's even arrived?
od: Chiara Russo, i wsp.
Wydane: (2024)

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
od: Chuanhai Wang, i wsp.
Wydane: (2022)

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17
od: Esther Wohlfarth, i wsp.
Wydane: (2023)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
od: Saoussen Oueslati, i wsp.
Wydane: (2022)

Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations
od: Klaudia Siwowska, i wsp.
Wydane: (2019)

Molecular analysis of T<sup>-</sup>B<sup>-</sup>NK<sup>+ </sup>severe combined immunodeficiency and Omenn syndrome cases in Saudi Arabia
od: Al-Kayal Fadi, i wsp.
Wydane: (2009)

Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations
od: Sven Hartmann, i wsp.
Wydane: (2022)